Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications
Phase 1/2 randomized, observer-blind clinical trial of a first-generation, mRNA-based vaccine against seasonal influenza and COVID-19 in healthy adults.
Journal: Human vaccines & immunotherapeutics
Published: February 02, 2026
Safety and immunogenicity of an mRNA-based RSV vaccine in seropositive children aged 12-59 months.
Journal: Human vaccines & immunotherapeutics
Published: September 15, 2025
Safety, Tolerability, and Immunogenicity of Revaccination With mRNA-1345, an mRNA Vaccine Against Respiratory Syncytial Virus, Administered 12 Months Following a Primary Dose in Adults Aged ≥50 Years.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: June 13, 2025
Immune correlates analysis of mRNA-1345 RSV vaccine efficacy clinical trial.
Journal: Nature communications
Published: December 06, 2024
Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trial.
Journal: The Lancet. Infectious diseases
Published: June 24, 2024
Safety and immunogenicity of an mRNA-based RSV vaccine in Japanese older adults aged ≥60 years: A phase 1, randomized, observer-blind, placebo-controlled trial.
Journal: Respiratory investigation
Published: March 06, 2024
Humoral Immunogenicity of mRNA-1345 RSV Vaccine in Older Adults.
Journal: The Journal of infectious diseases
Published: February 07, 2024
Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults.
Journal: The New England journal of medicine
Published: December 13, 2023
Last Updated: 09/26/2026